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INTRODUCTION

META -IODOBENZYLGUANIDINE
(MIBG) is a structural analogue of the neurotransmitter noradrenaline. It is recognised by the active noradrenaline transport system (uptake 1) and accumulates, therefore, in tissues of neuroendocrine origin [l] . In its radio-iodinated form, MIBG is used as a tumour seeking radio-pharmaceutical agent for the diagnosis and treatment of neuroblastoma and pheochromocytoma [2, 31.
It has been suggested that at least part of the clinical responses with [i3iI]MIBG are not related to the radio-emitting properties of this agent [4] . Indeed, unlabelled MIBG is known to inhibit cell proliferation of a large number of cell lines [5] . The antiproliferative effect of unlabelled MIBG has recently attracted more interest since a phase II study was started in which a number of carcinoid patients were treated with high doses (34 mg/m') of unlabelled MIBG before administration of [i3'I]MIBG [6] . We demonstrated earlier [7, and complex III (ubiquinol-ferricytochrome c-oxidoreductase) of the mitochondrial respiratory chain by MIBG was partially responsible for the decreased proliferation rate of the human lymphoblastic leukaemia cell line Molt-4 and the human neuroblastoma cell line SK-N-BE(2c).
During these studies, we observed that complete arrest of proliferation was achieved at MIBG concentrations that were approximately five times higher than the MIBG concentration required for complete inhibition of ATP synthesis. These findings strongly suggest that MIBG influences other processes in addition to mitochondrial oxidative phosphorylation.
Possible processes that may be influenced by MIBG in addition to mitochondrial ATP synthesis are the potentially harmful NADH-driven superoxide formation and lipid peroxidation that can be observed in submitochondrial particles [9, lo] . The rate of these two processes is enhanced when the electron transport from complex I to Qio is inhibited by et ~2. In order to determine whether inhibition of complex I and III by MIBG leads to an increase of NADH-driven formation of superoxide and NADH-driven peroxidation, we studied the effect of these two processes in submitochondrial particles (SMPs) by following the oxidation of adrenaline to adrenochrome as a measure of superoxide formation and the formation of malondialdehyde (MDA) as a measure of lipid peroxidation.
MATERIALS AND METHODS
SMPs were prepared according to Crane and associates [13] , The assay medium for superoxide production contained 1 mM adrenaline, 5 mM MgCla and 25 mM KaHP04/KH2P04, pH 7.4. SMPs (0.12 mg/ml) were preincubated with the various respiratory chain inhibitors (50 PM-3.2 mM MIBG or 10 pg/ml of either rotenone or antimycin) for 15 min at 37°C before reactions were started with 0.1 mM NADH. The rate of superoxide formation was determined by following the increase of absorbance due to the oxidation of adrenaline at 485-575 nm. The lipid peroxidation assay medium contained 0.2 mM FeC&, 2 mM ADP and 50 mM Tris-HCl, pH 7.4. SMPs (0.35 mg/ml) were pre-incubated with the various respiratory chain inhibitors (50 pM-3.2 mM MIBG or 10 ug/ml of either rotenone or antimycin)
for 15 min at 37°C before reactions were started with 0.5 mM NADH. After 5 min, reactions were terminated with 1 ml 50% acetic acid, and MDA concentrations were measured by the thiobarbiture acid method
[ 141. The effect of superoxide dismutase (SOD) on superoxide formation was measured by adding 10 ug/ml SOD to the assay medium just before reactions were started with NADH. The enzyme activity of complex I was measured as described before [7] ; the assay mixture contained 5 mM MgCla, 40 pM ubiquinonea (Sigma Chemical Company, St. Louis, U.S.A.), 10 ug antimycin, 0.05% lauryl maltoside (Sigma Chemical Company) and 25 mM K2HP041 KHaP04, pH 7.4. For each assay, 0.3 mg SMP protein was used. Reactions took place at 30°C and were started by adding NADH at a final concentration of 300 pM. The activity of the complex was measured by following the linear decrease in absorbance due to oxidation of NADH at 340 nm.
MIBG was purchased from EMKA-Chemie, Markgroningen, Germany. Figure 1 illustrates the results of the effect of MIBG on NADH-driven superoxide formation in SMPs. The formation of superoxide was maximal at an MIBG concentration of approximately 3 mM. This concentration was much higher than the concentration needed for maximal inhibition of the complex I activity (approximately 0.4 mM, Figure 1 ). The maximal effect of MIBG on superoxide formation was comparable to that of rotenone and antimycin ( Table 1) . Inhibition of both complex I and III by MIBG is unlikely to lead to an extra increase in the formation of superoxide, since a blockage of the electron flow at complex I leads to a lack of electron supply to complex III and thus \ .-.-. little or no effect due to inhibition of complex III by MIBG. This can also be observed when both rotenone (an inhibitor of complex I) and antimycin (an inhibitor of complex III) are present during the reaction (Table 1) . Addition of SOD to the assay medium showed that superoxide is indeed the cause of the oxidation of adrenaline (Table 1) . Figure 2 shows the effect of MIBG on the NADH-driven lipid peroxidation in SMPs. Increasing concentrations of MIBG led to an increase in the MDA formation from 0.85 to 1.45 nmol/mg/min. This increase was correlated to a 
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and III are inhibited by rotenone and antimycin, respectively (Table 2) .
DISCUSSION
This paper presents our studies on the effects of MIBG on NADH-driven superoxide formation and NADH-driven lipid peroxidation in beef heart submitochondrial particles. Both processes can be enhanced by inhibitors of complex I of the respiratory chain [9, 121. MIBG, being an inhibitor of complex I and III [7, 81, did 
